A drug delivery system targeting the tumour microenvironment produces outstanding therapeutic efficacy on triple-negative mammary and pancreatic models.

The development of efficient protocols for cancer diagnosis remains highly challenging. An emerging approach relies on the detection in exhaled breath of volatile organic compounds (VOC) produced by tumours.I nt his context, described here is anovel strategy in whichaVOC-based probe is converted selectively in malignant tissues,b yatumourassociated enzyme,for releasing the corresponding VOC. The latter is then detected in the exhaled breath as atumour marker for cancer diagnosis.T his approach allows the detection of several different tumours in mice,t he monitoring of tumour growth and tumour response to chemotherapy. Thus,t he concept of "induced volatolomics" provides an ew way to explore biological processes using VOC-based probes that could be adapted to many biomedical applications.